Ipsen S.A (F:I7G) — Market Cap & Net Worth
Market Cap & Net Worth: Ipsen S.A (I7G)
Ipsen S.A (F:I7G) has a market capitalization of $15.68 Billion (€13.42 Billion) as of April 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #1655 globally and #265 in its home market, demonstrating a 0.56% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ipsen S.A's stock price €162.80 by its total outstanding shares 82402504 (82.40 Million).
Ipsen S.A Market Cap History: 2015 to 2026
Ipsen S.A's market capitalization history from 2015 to 2026. Data shows growth from $5.37 Billion to $15.68 Billion (12.13% CAGR).
Ipsen S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ipsen S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.96x
Ipsen S.A's market cap is 2.96 times its annual revenue
Latest Price to Earnings (P/E) Ratio
30.64x
Ipsen S.A's market cap is 30.64 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.37 Billion | $1.52 Billion | $189.90 Million | 3.53x | 28.27x |
| 2016 | $6.09 Billion | $1.67 Billion | $225.90 Million | 3.65x | 26.97x |
| 2017 | $9.06 Billion | $2.01 Billion | $272.30 Million | 4.50x | 33.26x |
| 2018 | $9.79 Billion | $2.35 Billion | $389.50 Million | 4.17x | 25.15x |
| 2019 | $7.17 Billion | $2.69 Billion | -$50.70 Million | 2.66x | N/A |
| 2020 | $6.26 Billion | $2.69 Billion | $548.00 Million | 2.33x | 11.43x |
| 2021 | $7.54 Billion | $3.00 Billion | $646.60 Million | 2.51x | 11.66x |
| 2022 | $9.45 Billion | $3.16 Billion | $648.60 Million | 2.99x | 14.57x |
| 2023 | $10.23 Billion | $3.31 Billion | $644.40 Million | 3.09x | 15.88x |
| 2024 | $10.60 Billion | $3.57 Billion | $345.90 Million | 2.96x | 30.64x |
Competitor Companies of I7G by Market Capitalization
Companies near Ipsen S.A in the global market cap rankings as of April 19, 2026.
Key companies related to Ipsen S.A by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #430 globally with a market cap of $53.93 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #443 globally with a market cap of $52.58 Billion USD ( CN¥359.33 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #519 globally with a market cap of $45.88 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #546 globally with a market cap of $43.42 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #430 | Zoetis Inc | NYSE:ZTS | $53.93 Billion | $122.38 |
| #443 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $52.58 Billion | CN¥56.33 |
| #519 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $39.96 |
| #546 | Haleon plc | NYSE:HLN | $43.42 Billion | $9.75 |
Ipsen S.A Historical Marketcap From 2015 to 2026
Between 2015 and today, Ipsen S.A's market cap moved from $5.37 Billion to $ 15.68 Billion, with a yearly change of 12.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €15.68 Billion | +37.15% |
| 2025 | €11.44 Billion | +7.91% |
| 2024 | €10.60 Billion | +3.56% |
| 2023 | €10.23 Billion | +8.26% |
| 2022 | €9.45 Billion | +25.40% |
| 2021 | €7.54 Billion | +20.35% |
| 2020 | €6.26 Billion | -12.61% |
| 2019 | €7.17 Billion | -26.84% |
| 2018 | €9.79 Billion | +8.14% |
| 2017 | €9.06 Billion | +48.68% |
| 2016 | €6.09 Billion | +13.49% |
| 2015 | €5.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 18th, 2026 the market cap of Ipsen S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.68 Billion USD |
| MoneyControl | $15.68 Billion USD |
| MarketWatch | $15.68 Billion USD |
| marketcap.company | $15.68 Billion USD |
| Reuters | $15.68 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ipsen S.A
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more